COMPANY:

Volition

"VolitionRx...today provides an update on the significant commercial and scientific progress of its Nu.Q® Discover program...With an estimated total addressable market of $200 million annually [1], Nu.Q® Discover targets a smaller market than our other larger pillars, but it is proving to be a strong source of early revenue and is validating the wide applicability and utility of our Nu.Q® platform with some of the world's biggest healthcare companies. With a powerful portfolio of 14 state-of-the-art immunoassays, Nu.Q® Discover is now serving over 20 clients worldwide, accelerating disease research and drug development across multiple therapeutic areas."

"VolitionRx...today announces that Chief Commercial Officer, Gael Forterre, has issued a commercial update on Volition's Nu.Q® NETs product...A Message from our Chief Commercial Officer - 'As was stated in our shareholder update recently, 2025 is a pivotal year for Volition as we focus on commercializing our groundbreaking Nu.Q® platform in the human diagnostics market. Today, I would like to focus on the large, and very broad Nu.Q® NETs (NETosis) opportunity.' "

"VolitionRx Limited...today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers. This could potentially be used as a standalone pan-cancer test or, given its low false positive rate among healthy people, be licensed out for use in conjunction with other liquid biopsy technologies to improve accuracy."

"VolitionRx Limited...announces first patient enrollment in a clinical study evaluating the company's proprietary Nu.Q Cancer technology for distinguishing between malignant and benign pulmonary nodules in patients undergoing low-dose computed tomography (LDCT) screening for lung cancer....We are delighted to have recruited the first patient into our 500-patient prospective validation study.'"

"VolitionRx...today announces that it has signed an agreement with a leading pharmaceutical company to utilize Volition's Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study. The Nu.Q® Discover program provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to market ready...Following a successful pilot study, two of Volition's Nu.Q® Discover assays were selected for use in this study. It is expected to be completed over a 12-18 month period, generating significant revenue for Volition for this study alone, with further projects being discussed."

"VolitionRx Limited...today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected of lung cancer...The 800-patient prospective study was led by Professor Jin-Shing Chen and his team at National Taiwan University Hospital...Findings published in a paper that is currently undergoing peer review and accessible on MedRXIV, conclude that a panel of two Nu.Q® nucleosome quantification assays (H3.1 and H3K27Me3) showed a diagnostic sensitivity of 92% and a Positive Predictive Value of 89% in identifying cancerous nodules when used in combination with LDCT screening."

"VolitionRx Limited...is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain...Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood. Cancer-derived ctDNA fragments are then extracted after removal of all normal background DNA of the same sequence for detection with a simple, low cost PCR test."

"VolitionRx Limited...has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023, the annual congress of the European Society for Medical Oncology...Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood. Cancer derived ctDNA fragments are then extracted after removal of all normal background DNA of the same sequence for detection with a simple, low cost PCR test."